Skip to main content

Human Cytokeratin 19 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB3506

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB3506
MAB3506-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Rat

Applications

Validated:

Immunocytochemistry, Immunohistochemistry, Western Blot

Cited:

ELISA Capture, ELISA Detection, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # BA17

Product Specifications

Immunogen

Mammary organoids

Specificity

Detects human Cytokeratin 19.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human Cytokeratin 19 Antibody

Cytokeratin 19 antibody in MDA-MB-231 Human Cell Line by Immunocytochemistry (ICC).

Cytokeratin 19 in MDA‑MB‑231 Human Cell Line.

Cytokeratin 19 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using Mouse Anti-Human Cytokeratin 19 Monoclonal Antibody (Catalog # MAB3506) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Cytokeratin 19 antibody in Human Breast Cancer Tissue by Immunohistochemistry (IHC-P).

Cytokeratin 19 in Human Breast Cancer Tissue.

Cytokeratin 19 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human Cytokeratin 19 Monoclonal Antibody (Catalog # MAB3506) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes of cancer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Applications for Human Cytokeratin 19 Antibody

Application
Recommended Usage

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed MDA-MB-231 human breast cancer cell line

Immunohistochemistry

5-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human breast cancer tissue

Western Blot

Bartek J. et al. (1985) Int J Cancer. 36(3):299. This application was not tested by R&D Systems.

Reviewed Applications

Read 2 reviews rated 5 using MAB3506 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Cytokeratin 19

Cytokeratin 19, a type I intermediate filament protein, is the smallest known acidic cytokeratin. The degree of keratin 19 positivity in breast cancer distinguishes malignant from benign tumours.

Alternate Names

CK19, EndoC, K19, Krt19

Entrez Gene IDs

3880 (Human); 16669 (Mouse)

Gene Symbol

KRT19

Additional Cytokeratin 19 Products

Product Documents for Human Cytokeratin 19 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Cytokeratin 19 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...